10-QPeriod: Q1 FY2025

BeOne Medicines Ltd. Quarterly Report for Q1 Ended Mar 31, 2025

Filed May 7, 2025For Securities:ONCBEIGF

Summary

Beigene, Ltd. (ONC) demonstrated a significant financial turnaround in the first quarter of 2025, reporting GAAP net income of $1.27 million compared to a net loss of $251.15 million in the prior year period. This improvement was driven by a substantial 48.6% increase in total revenues to $1.12 billion, primarily fueled by a 48.4% surge in product revenue to $1.11 billion. The company's flagship product, BRUKINSA®, saw a remarkable 62.1% increase in global sales, reaching $791.7 million, and now leads in new patient starts and market share in the U.S. for BTKi. Despite the revenue growth and return to profitability, operating expenses, particularly research and development, saw a modest increase of 4.6% to $481.9 million, and selling, general, and administrative expenses increased by 7.5% to $459.3 million, reflecting continued investment in pipeline advancement and commercial expansion. The company ended the quarter with a strong liquidity position, holding $2.53 billion in cash, cash equivalents, and restricted cash, while successfully reducing its total debt. The strategic focus on expanding its oncology pipeline, coupled with positive sales momentum for its key products, positions Beigene for continued growth.

Financial Highlights

49 data points
Beta

Revenue

$1.12B

0.9% Gross Margin

Net Income

$1.27M

0.0% Net Margin

EPS (Diluted)

$0.00

Total Assets

$5.84B

Cash & Equivalents

$2.52B

Free Cash Flow

-$12.32M

Financial Statements
Beta
Revenue$1.12B
Gross Profit$952.28M
R&D Expenses$481.89M
SG&A Expenses$459.29M
Operating Expenses$941.17M
Operating Income$11.10M
Interest Expense$12.96M
Net Income$1.27M
Shares Outstanding (Basic)1.39B
Shares Outstanding (Diluted)1.45B

Key Highlights

  • 1Total revenues increased by 48.6% to $1.12 billion for the three months ended March 31, 2025, compared to $751.7 million in the prior-year period.
  • 2Net product revenue grew by 48.4% to $1.11 billion, driven by strong performance across key products.
  • 3BRUKINSA® global sales increased by 62.1% to $791.7 million, reflecting continued demand and market share gains.
  • 4The company achieved GAAP net income of $1.27 million, a significant improvement from a net loss of $251.15 million in the same period last year.
  • 5Operating expenses increased by 6.0% to $941.2 million, with R&D expenses up 4.6% to $481.9 million and SG&A expenses up 7.5% to $459.3 million.
  • 6Cash, cash equivalents, and restricted cash stood at $2.53 billion as of March 31, 2025.
  • 7The company announced shareholder approval to rename itself BeOne Medicines Ltd. and redomicile to Switzerland.

Frequently Asked Questions